

# Diagnostics Defining Therapy™

**PlexPCR®** tests combine multiple, clinically relevant infectious disease targets into a single test solution - simplifying patient diagnostics and streamlining patient management.

Respiratory Testing				
Name	Advantage	Compatible	Size	Cat#
<b>PlexPCR®</b> RespiVirus*	Two-well test combined with SpeedX automated analysis software. Process up to 186 samples in an 8hr shift with a single operator and platform. Combined with <b>PlexPrep™</b> automation process up to 1536 samples in an 8hr shift with a single operator.	LC480 II	192 reactions	1201192
	<b>Description:</b> Detect and differentiate Influenza A, Influenza B, Rhinoviruses (A & B), Respiratory Syncytial Viruses (A & B), Human metapneumovirus, Adenoviruses (B & C), and Human parainfluenza viruses 1, 2, 3 and 4.			
<b>PlexPCR®</b> SARS-CoV-2*	Dual target, single well test with scalable workflow for surge capacity. Regular performance monitoring for confidence in variant detection.	LC480 II/ CFX	384 reactions	1301384
	<b>Description:</b> Detect COVID-19 causative coronavirus, SARS-CoV-2 with dual gene targets (RdRp/ORF1ab) and RNA-based internal control			
RESEARCH ONLY				
<b>PlexPrime®</b> SARS-CoV-2 Genotyping	Investigate positive SARS-CoV-2 samples for relevant and circulating COVID-19 mutations linked to variants of concern(VOC)	All platforms	200 reactions	Enquiry
	<b>Description:</b> Single-well and multiplex reflex solutions to determine presence of key mutations linked to circulating VOC. Including alpha/beta/gamma+, delta+, and more in development.			
COMING SOON				
RespiBacteria <sup>§</sup>	Comprehensive molecular solution to detect and distinguish common bacterial causes of respiratory infection.			

Accessories				
Name	Description	Compatible	Size	Cat#
<b>PlexPrep™</b>	Compact, simple-to-use robotics for precision liquid handling.	Enquire	63.5cm x 53.4cm, 41.6kg	6600200-01
<b>ResistancePlus®</b> MG Positive Control	Positive control DNA for wild type (23S rRNA) or mutant (23S rRNA mutations: A2058G, A2059G, A2058T, A2058C, A2059C) <i>M. genitalium</i> .	All platforms	10 reactions	95001
<b>ResistancePlus®</b> GC Control	Negative and Positive control DNA for <i>N. gonorrhoeae</i> ( <i>porA</i> & <i>opa</i> ), and <i>gyrA</i> S91 wildtype or <i>gyrA</i> S91F mutant targets.	All platforms	10 reactions	95003
<b>PlexPCR®</b> RespiVirus Positive Control	Positive control DNA for FluA, FluB, RhV, RSV, HMPV, AdV and HPIV 1-4 targets.	All platforms	10 reactions	95002
<b>PlexPCR®</b> Colour Compensation Kit	For the generation of a <b>PlexPCR®</b> Colour Compensation file. Supplied by request for LightCycler instrumentation.	LC480 II/ LC480 I/z480	2 reactions	90001

SpeedX tests go beyond simple detection, providing clinically relevant information to support patient management and inform treatment decisions.

**ResistancePlus®** tests combine organism detection with genetic markers linked to antibiotic susceptibility or resistance — providing valuable information to guide treatment decisions.

Sexual Health Testing				
Name	Advantage	Compatible	Size	Cat#
<b>ResistancePlus® GC*</b>	Provide therapeutic guidance for gonorrhoea infections and adhere to EU guidelines recommending preferential ciprofloxacin treatment. <sup>1</sup> All <b>ResistancePlus®</b> tests run on uniform profiles for simplified lab workflow.	LC480 II/ z480	100 reactions	2011001
			25 reactions	2011025
		ABI 7500/ 7500 Fast/Dx	100 reactions	2013001
			25 reactions	2013025
		CFX96 IVD/ CFX96 Touch	100 reactions	2015001
			25 reactions	2015025
<b>Description:</b> <i>Neisseria gonorrhoeae</i> (GC) and <i>gyrA</i> markers linked to ciprofloxacin susceptibility or resistance.				
<b>ResistancePlus® MG*</b>	Provide therapeutic guidance for <i>Mycoplasma genitalium</i> (Mgen) infections. Resistance Guided Therapy is clinically demonstrated to improve patient cure rate <sup>2</sup> and is recommended in EU and local management guidelines. <sup>3-6</sup> All <b>ResistancePlus®</b> tests run on uniform profiles for simplified lab workflow.	LC480 II/ z480	100 reactions	20001L-01
			25 reactions	2000125
		ABI 7500/ 7500 Fast/Dx	100 reactions	2000201
			25 reactions	2000225
		CFX96 IVD/ CFX96 Touch	100 reactions	2000301
			25 reactions	2000325
<b>Description:</b> <i>Mycoplasma genitalium</i> (Mgen) and 5 mutations linked to macrolide (azithromycin) resistance.				
<b>PlexPCR® VHS*</b>	Confidently distinguish atypical lesions with definitive molecular diagnostics. Reduce risk of syphilis outbreaks with PCR sentinel screening, offering early infection detection on all lesions. <sup>7</sup> Two tests, one platform - software options can exclude <i>Treponema pallidum</i> detection if required.	LC 480 II	100 reactions	1121001
		ABI 7500/ 7500 Fast/Dx	100 reactions	1123001
		CFX96 IVD/ CFX96 Touch	100 reactions	1125001
<b>Description:</b> Detect and differentiate herpes simplex virus types 1 & 2 (HSV-1 & HSV-2), Varicella zoster virus (VZV), and <i>Treponema pallidum</i> (syphilis).				
<b>PlexPCR® HSV-1&amp;2, VZV*</b>	Detect and differentiate HSV-1, HSV-2 and VZV. Does not require additional software.	LC480 II	100 reactions	11101L-01

\*Not available in the U.S. §Not yet commercially available. ~Not available in the U.S. TGA anticipated 2021

**References:** 1. Bignell C & Unemo M. 2012 European Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults. 2. Read TRH et al. CID 2019; 68(4):554-560. 3. Jensen J, Cusini M, Gomberg M. 2016 European guideline on Mycoplasma genitalium infections. 4. Horner PJ et al. 2016 European guideline on the management of non-gonococcal urethritis. 5. <https://www.sfdermato.org/actualites/communiqu-e-commun-gridist-et-sfd.html>. 6. Soni S et al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018). 7. Acquah R et al. Sex Transm Infect 2017;93:326.

All kits are developed and manufactured by SpeedX Pty Ltd, Sydney. **PlexPCR®**, **ResistancePlus®**, **PlexPrep™** & **SpeedX®** are registered trademarks of SpeedX Pty Ltd. Other copyright and trademarks are the property of the respective owners. SpeedX Pty. Ltd. products may be covered by one or more local or foreign patents. Visit [www.plexpcr.com/patents](http://www.plexpcr.com/patents) for comprehensive patent information.

**Australia - SpeedX Pty. Ltd.**  
+61 (0)2 9209 4170  
[sales@speedx.com.au](mailto:sales@speedx.com.au)

Suite 102, National Innovation Centre  
4 Cornwallis Street, Sydney NSW 2015 Australia

**Europe - SpeedX Ltd.**  
+44 (0)333 577 5210  
[sales.uk@speedx.com.au](mailto:sales.uk@speedx.com.au)

Acre House 11/15 William Road  
London NW1 3ER United Kingdom